Anticoagulation in Patients with Heparin-Induced Thrombocytopenia undergoing Percutaneous Coronary Angiography and Interventions

Author(s): Alexander Joost, Volkhard Kurowski, Peter W. Radke.

Journal Name: Current Pharmaceutical Design

Volume 14 , Issue 12 , 2008

Become EABM
Become Reviewer

Abstract:

The administration of heparins (unfractionated or fractionated) represents the current standard as anticoagulant treatment during percutaneous coronary intervention in different clinical settings (elective cases and acute coronary syndrome). Since the incidence of heparin-induced thrombocytopenia (HIT) is expected to range between 0.1 and 5%, the application of an appropriate anticoagulant agent has become a mandatory issue. This review will provide current pathophysiological insights of HIT as well as contemporary alternative anticoagulant strategies during PCI in patients with or at risk of HIT.

Keywords: Heparin-induced-thrombocytopenia, HIT, PCI, argatroban, bivalirudin, lepirudin, danaparoid, fondaparinux

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 14
ISSUE: 12
Year: 2008
Page: [1176 - 1185]
Pages: 10
DOI: 10.2174/138161208784246126
Price: $58

Article Metrics

PDF: 4